JP2021534115A - Ｂ細胞悪性腫瘍の処置 - Google Patents

Ｂ細胞悪性腫瘍の処置 Download PDF

Info

Publication number
JP2021534115A
JP2021534115A JP2021506716A JP2021506716A JP2021534115A JP 2021534115 A JP2021534115 A JP 2021534115A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021534115 A JP2021534115 A JP 2021534115A
Authority
JP
Japan
Prior art keywords
alkyl
enantiomers
heterocyclyl
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534115A5 (enExample
Inventor
ピー． ゴールド，ダニエル
Original Assignee
エムイーアイ ファーマ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムイーアイ ファーマ，インク． filed Critical エムイーアイ ファーマ，インク．
Publication of JP2021534115A publication Critical patent/JP2021534115A/ja
Publication of JP2021534115A5 publication Critical patent/JP2021534115A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021506716A 2018-08-14 2019-08-13 Ｂ細胞悪性腫瘍の処置 Pending JP2021534115A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (2)

Publication Number Publication Date
JP2021534115A true JP2021534115A (ja) 2021-12-09
JP2021534115A5 JP2021534115A5 (enExample) 2022-08-19

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506716A Pending JP2021534115A (ja) 2018-08-14 2019-08-13 Ｂ細胞悪性腫瘍の処置

Country Status (14)

Country Link
US (1) US20210299134A1 (enExample)
EP (1) EP3836935A4 (enExample)
JP (1) JP2021534115A (enExample)
KR (1) KR20210043635A (enExample)
CN (1) CN112888441A (enExample)
AU (1) AU2019321432A1 (enExample)
BR (1) BR112021002760A2 (enExample)
CA (1) CA3109184A1 (enExample)
IL (1) IL280726A (enExample)
MA (1) MA53236A (enExample)
MX (1) MX2021001606A (enExample)
SG (1) SG11202101450VA (enExample)
TW (1) TW202021591A (enExample)
WO (1) WO2020036999A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11365252B2 (en) * 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy

Also Published As

Publication number Publication date
CA3109184A1 (en) 2020-02-20
IL280726A (en) 2021-03-25
SG11202101450VA (en) 2021-03-30
TW202021591A (zh) 2020-06-16
EP3836935A1 (en) 2021-06-23
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
MX2021001606A (es) 2021-04-19
KR20210043635A (ko) 2021-04-21
BR112021002760A2 (pt) 2021-05-11
CN112888441A (zh) 2021-06-01
WO2020036999A1 (en) 2020-02-20
MA53236A (fr) 2021-06-23
AU2019321432A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
US12157735B2 (en) Compounds for targeted degradation of BRD9
US12590062B2 (en) PD-1/PD-L1 inhibitors
JP6779870B2 (ja) 抗増殖性化合物及びその使用方法
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
CN112585136B (zh) 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
AU2021257373B2 (en) Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators
TW201737913A (zh) Tank－結合激酶抑制劑化合物
JP2021517116A (ja) 併用療法
IL272166B (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
JP2024522189A (ja) Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN112739420A (zh) 苯氧基-吡啶基-嘧啶化合物及使用方法
JP2025538228A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
JP2024522188A (ja) Ｆｇｆｒ阻害剤としての三環式ヘテロ環
WO2025059245A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
KR20210043635A (ko) B 세포 악성 종양의 치료
CN112689528B (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
JP2021534116A (ja) 再発性の濾胞性リンパ腫の処置
JP2021534114A (ja) 併用療法
KR20260004307A (ko) 다환성 irak 및 flt3 억제 화합물 및 이의 용도
KR20230135541A (ko) 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
HK40076587A (en) Pd-1/pd-l1 inhibitors
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220810

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231221